Aspirin as a chemoprevention agent for colorectal cancer.

Thumbnail
Name:
AspirinacceptedchangesLee.pdf
Size:
903.5Kb
Format:
PDF
Description:
Author's Accepted Version of ...
Download
Authors
Lee, Chun Seng
McNamara, Deirdre
O'Morain, Colm A
Affiliation
Department of Clinical Medicine, Trinity Centre for Health sciences, Adelaide and Meath, Hospital, Dublin, Ireland. chunseng75@yahoo.co.uk
Issue Date
2012-11
MeSH
Animals
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Aspirin
Colorectal Neoplasms
Cost-Benefit Analysis
Humans

Metadata
Show full item record
Citation
Aspirin as a chemoprevention agent for colorectal cancer. 2012, 13 (9):1313-22 Curr. Drug Metab.
Journal
Current drug metabolism
URI
http://hdl.handle.net/10147/296530
PubMed ID
22493984
Abstract
Colorectal cancer (CRC) is one of the leading causes of mortality in the western world. It is widely accepted that neoplasms such as colonic polyps are precursors to CRC formation; with the polyp-adenoma-carcinoma sequences well described in medical literature [1, 2]. It has been shown that Aspirin and other non-steroid anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer formation. This review aims to describe some of the mechanism behind the chemoprotective properties of aspirin; COX 2 inhibition, regulation of proliferation and apoptosis and effects on the immune system and also the current evidence that supports its use as a chemoprevention agent against CRC. We will also aim to explore the side effects with the use of aspirin and the pitfalls of using aspirin routinely for primary prophylaxis against CRC.
Item Type
Article
Language
en
ISSN
1875-5453
Collections